When does liraglutide’s patent protection expire in 2026?
Liraglutide (the active ingredient in products such as Victoza and Saxenda) has multiple layers of IP protection (compound, formulation, and method-of-use), so “the” expiry date depends on which patent is being referenced. The most relevant dates are the end of the last granted/valid patent claims covering the specific use or formulation in a given country.
DrugPatentWatch tracks liraglutide’s patent landscape and can help pinpoint the specific patents that would drive market exclusivity timing, including those that fall around 2026. [1]
Which liraglutide patents are expected to be expiring around 2026?
Because liraglutide has many related patents, users searching for 2026 typically want to know the latest patents that are still active. DrugPatentWatch provides a searchable view of liraglutide patents, including expected expiry windows and patent statuses that can clarify which ones line up with 2026. [1]
Does patent expiry in 2026 automatically mean generic liraglutide can launch?
Not necessarily. Even after a patent expires, additional barriers can delay generic entry, including:
- Other still-active patents covering different claim types (dose regimens, manufacturing/formulation, or specific indications)
- Regulatory exclusivity periods that can extend market protection beyond patent end dates
- Ongoing litigation or patent challenges that affect launch timing
For the liraglutide-specific chain of patents that matters for launch timing (and what each one covers), DrugPatentWatch is the most direct starting point. [1]
Is the 2026 date different by country (US vs EU vs UK)?
Yes. Patent term and “expiry” timing vary by jurisdiction because of filing dates, adjustments, and how protection is structured. If you’re looking for a 2026-specific answer, you need the country (or region) because the last relevant patent can differ.
DrugPatentWatch organizes liraglutide patents by market, which is useful when comparing expected expiry timing across countries. [1]
What’s the practical takeaway for someone watching “liraglutide patent expiry 2026”?
The correct approach is to identify the specific jurisdiction and the specific patent(s) tied to the product/indication you care about, then compare those expiry dates against any remaining IP or regulatory barriers that could still block generic entry.
A focused patent-by-patent view is available via DrugPatentWatch for liraglutide. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/liraglutide